인공 요도 괄약근 시장 : 제품 유형, 구성 요소 유형, 작용 기전, 재질 유형, 성별, 유통 채널, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Artificial Urinary Sphincters Market is projected to grow by USD 763.18 million at a CAGR of 7.46% by 2032.

Artificial urinary sphincters (AUS) are implantable continence devices used primarily for moderate-to-severe stress urinary incontinence, especially in men after prostate cancer treatment or other sphincter-compromising surgery. The category is clinically important because stress urinary incontinence can limit mobility, work participation, sleep, mental health, and long-term quality of life, creating a sustained need for reliable urological implants and reconstructive continence care.

In urology guidelines and peer-reviewed clinical practice, the AUS remains the reference standard for appropriately selected men with severe post-prostatectomy incontinence. Demand is shaped by aging populations, prostate cancer survivorship, higher expectations for quality-of-life restoration, and broader access to reconstructive urology. Growth is also tied to surgeon training, reimbursement coverage, infection-control protocols, and device durability, because artificial urinary sphincter implantation requires specialized patient selection, operative skill, patient education on device use, and lifelong follow-up for revision, infection, erosion, or mechanical performance concerns.

Transformative Shifts in the AUS Landscape

The artificial urinary sphincter landscape is shifting from procedure availability toward measurable outcomes, patient-reported improvement, and lifecycle management. Hospitals and ambulatory surgery centers are increasingly evaluated on complication reduction, readmission avoidance, infection prevention, and long-term device performance, making preoperative counseling and post-implant surveillance central to adoption of AUS surgery.

Technology adoption is also changing. Established hydraulic cuff systems remain the benchmark, while innovation is focused on easier activation, improved cuff design, pressure optimization, antibiotic-conscious workflows, and materials intended to reduce erosion and infection risk. The market is also influenced by the rise of male sling alternatives for selected patients, growing salvage surgery needs after pelvic radiation, greater attention to frailty and comorbidities in older patients, and wider use of telehealth for follow-up. These shifts favor stakeholders that combine durable implants, urologist education, real-world evidence generation, and structured patient support.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is not replacing the artificial urinary sphincter, but it is beginning to influence the care pathway around AUS candidates. AI-enabled analytics can support risk stratification by integrating age, prior radiation, diabetes, urethral surgery history, anticoagulation status, mobility, cognitive readiness for device operation, and severity of leakage to identify patients who may need enhanced counseling or specialized reconstructive expertise.

In clinical operations, machine learning can help forecast operating room demand, revision risk, inventory needs, and follow-up adherence. Natural language processing can extract continence outcomes, pad usage, patient-reported satisfaction, and adverse events from clinical notes, improving real-world evidence generation. AI may also support remote monitoring programs by flagging patients reporting pain, voiding difficulty, recurrent leakage, hematuria, or signs of infection. The cumulative impact is a more data-driven AUS ecosystem, where patient selection, outcome tracking, surgical planning, and revision management become more precise and scalable.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America remains the most established regional market for artificial urinary sphincters, supported by high prostate cancer survivorship, advanced reconstructive urology networks, and broad use of guideline-based treatment pathways. The region benefits from academic medical centers, ambulatory surgical capacity, structured continence care, and established reimbursement mechanisms for implantable urological devices. The United States is especially important because large urology groups, tertiary hospitals, cancer survivorship programs, and private and public payers create a structured environment for AUS implantation, revision surgery, infection management, and outcomes research, while Canada's access is shaped by publicly funded care pathways and provincial surgical capacity.

Europe shows mature demand for artificial urinary sphincters, with adoption concentrated in countries that have strong public reimbursement, specialized pelvic reconstructive urology, and centralized prostate cancer care. The European clinical environment emphasizes device safety, post-market surveillance, clinical evidence, and standardized quality systems. Asia-Pacific is expanding as Japan, Australia, South Korea, China, India, and ASEAN economies increase access to prostate cancer treatment, functional urology services, and tertiary surgical infrastructure, although adoption varies significantly by reimbursement, patient affordability, procurement processes, and surgeon training. Latin America, the Middle East, and Africa represent longer-term opportunities, led by private hospitals, government-funded specialty centers, and tertiary academic institutions; however, affordability, procurement reliability, specialist availability, revision-care capacity, and follow-up infrastructure remain key constraints to broader AUS adoption.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Within the European Union and G7, artificial urinary sphincter demand is supported by aging demographics, high prostate cancer diagnosis and treatment rates, established health technology assessment processes, and access to reconstructive urologists. These markets place strong emphasis on clinical evidence, device safety, surgeon credentialing, reimbursement justification, infection prevention, and post-market surveillance. NATO membership itself is not a healthcare purchasing framework, but many NATO countries overlap with high-income markets where standardized procurement, hospital quality systems, military and veteran healthcare networks, and advanced continence-care pathways can influence access to AUS implantation and revision services.

BRICS countries offer significant procedural potential because of large populations, expanding cancer care, and rising investment in specialty surgery, but adoption is uneven due to reimbursement gaps, out-of-pocket exposure, and concentration of reconstructive urology expertise in major cities. ASEAN markets are developing through private-sector growth, medical tourism hubs, and expanding tertiary urology capacity, while access remains differentiated by income level and availability of trained implanting surgeons. GCC countries benefit from government-funded tertiary care, high investment in advanced urology services, and referral-based specialist hospitals, making them important centers for premium implantable urology technologies where procurement, clinician training, and long-term service support are clearly established.

Key Country Insights Across Major AUS Markets

The United States is the leading country market for artificial urinary sphincters because of high procedural specialization, extensive prostate cancer survivorship care, broad reconstructive urology expertise, and a strong base of implanting urologists. Canada follows with publicly funded access shaped by provincial capacity, referral patterns, and wait times. Mexico and Brazil show demand in private hospitals, major academic centers, and metropolitan specialty clinics where reconstructive urology and implantable device procurement are available. In Latin America, access is closely linked to private insurance, urban specialty concentration, and the ability to support long-term revision care.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from structured prostate cancer pathways, aging male populations, and experienced urology centers, although reimbursement approval, waiting lists, and regional access differ by system. Germany and France have strong specialist hospital networks, the United Kingdom emphasizes guideline-based continence management within public care, and Italy and Spain combine public hospital pathways with experienced regional centers. Russia has demand concentrated in large urban specialty hospitals where implant access and reconstructive expertise are available. In Asia-Pacific, Japan, Australia, and South Korea have advanced urology infrastructure, aging populations, and mature cancer survivorship services, while China and India represent high-potential markets where scale is significant but access depends on affordability, trained surgeons, tertiary-care availability, reimbursement expansion, and patient awareness of post-prostatectomy incontinence treatment options.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based differentiation rather than relying only on device familiarity. The most defensible strategy is to generate long-term real-world data on continence improvement, revision rates, infection, erosion, device survival, patient satisfaction, pad-use reduction, and cost of care across diverse patient groups, including men with prior radiation, diabetes, urethral stricture history, or complex reconstructive needs.

Manufacturers and healthcare stakeholders should invest in surgeon education, proctoring, standardized implantation protocols, infection-control pathways, revision readiness, and patient activation training because AUS outcomes depend heavily on technique, appropriate selection, and follow-up. Commercial teams should align with reconstructive urology centers, cancer survivorship programs, continence clinics, and payers using value narratives that emphasize quality-of-life restoration and reduced dependence on pads or external containment. In emerging markets, success will require tiered access strategies, local distributor quality control, repair or revision support, responsible inventory management, and clear patient-selection guidance that reduces complications and supports sustainable adoption.

Research Methodology

This executive summary is built from a structured review of evidence-based sources commonly used in medical device market assessment, including urology society guidance, peer-reviewed studies on artificial urinary sphincter outcomes, regulatory and reimbursement context, hospital adoption patterns, prostate cancer survivorship trends, demographic aging indicators, and regional healthcare infrastructure evidence.

The analysis emphasizes verified clinical and market drivers rather than speculative market sizing. It evaluates demand through disease burden, treatment pathway maturity, specialist availability, reimbursement feasibility, device lifecycle needs, patient suitability, revision requirements, and real-world barriers to access. Regional, group, and country insights were synthesized by comparing healthcare capacity, urology specialization, cancer survivorship infrastructure, procurement dynamics, affordability, and follow-up systems relevant to AUS implantation and revision care.

Conclusion: The Future of Artificial Urinary Sphincters

Artificial urinary sphincters occupy a durable and clinically validated position in the management of severe stress urinary incontinence, particularly after prostate cancer treatment. The market's long-term relevance is supported by aging populations, survivorship-focused urology, patient demand for restored continence, and the continued need for specialized reconstructive solutions when conservative measures or less invasive procedures are insufficient.

The strongest opportunities will come from pairing proven device performance with better patient selection, surgeon training, outcomes analytics, and regional access strategies. As artificial intelligence, real-world evidence, and value-based care mature, AUS stakeholders that demonstrate measurable quality-of-life benefit, durable safety, responsible lifecycle support, and reliable revision-care pathways will be best positioned to lead in artificial urinary sphincter innovation and adoption.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Artificial Urinary Sphincters Market, by Product Type

• 7.1. Single-Cuff Artificial Urinary Sphincters
• 7.2. Dual-Cuff Artificial Urinary Sphincters

8. Artificial Urinary Sphincters Market, by Component Type

• 8.1. Occlusive Cuff
• 8.2. Pressure-Regulating Balloon
• 8.3. Control Pump
• 8.4. Electronic Control Unit

9. Artificial Urinary Sphincters Market, by Mechanism of Action

• 9.1. Hydraulic Pressure Control
• 9.2. Mechanical Compression Systems
• 9.3. Electromechanical / Sensor-Controlled Systems

10. Artificial Urinary Sphincters Market, by Material Type

• 10.1. Silicone
• 10.2. Polyurethane
• 10.3. Biocompatible Polymers

11. Artificial Urinary Sphincters Market, by Gender

• 11.1. Female
• 11.2. Male

12. Artificial Urinary Sphincters Market, by Distribution Channel

• 12.1. Direct Sales
• 12.2. Distributors
• 12.3. Online Sales

13. Artificial Urinary Sphincters Market, by Application

• 13.1. Neurogenic Bladder Dysfunction
• 13.2. Stress Urinary Incontinence

14. Artificial Urinary Sphincters Market, by End User

• 14.1. Ambulatory Surgical Centers
  • 14.1.1. Freestanding
  • 14.1.2. Hospital Affiliated
• 14.2. Clinics
  • 14.2.1. Multispecialty Clinics
  • 14.2.2. Urology Clinics
• 14.3. Hospitals
  • 14.3.1. Private Hospitals
  • 14.3.2. Public Hospitals

15. Artificial Urinary Sphincters Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Artificial Urinary Sphincters Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Artificial Urinary Sphincters Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Affluent Medical
• 19.2. Albyn Medical Ltd.
• 19.3. Andromeda Medizinische Systeme GmbH
• 19.4. Anhui Longterm Medical Products Co., Ltd.
• 19.5. Boston Scientific Corporation
• 19.6. Dualis MedTech GmbH
• 19.7. GT Urological LLC
• 19.8. LABORIE Medical Technologies Inc.
• 19.9. MyoPowers Medical Technologies SAS
• 19.10. Promedon S.A.
• 19.11. Rigicon Inc.
• 19.12. Uromedical AG
• 19.13. UroMems
• 19.14. Zephyr Surgical Implants AG